Who
Brandi Roberts
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Definium Therapeutics; Executive VP and CFO, Longboard Pharmaceuticals; Director, TFF Pharmaceuticals; CFO & SVP Finance, Lineage Cell Therapeutics; SVP & Chief Financial Officer, REVA Medical; Chief Financial Officer & SVP, Savara.
In numbers
- Trades disclosed
- 50
- Buys
- 5
- Sells
- 2
- Bought
- $37K
- Sold
- $518K
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 15 Jun 2011
- Last trade
- 25 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $123K3,377 at $36.57 | filing |
| 25 Sep 2026filed 29 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $123K3,377 at $36.57 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 14 Sep 2026filed 14 Sep 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 12 Aug 2026filed 12 Aug 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $136K3,013 at $45.03 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Sold | $136K3,013 at $45.03 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | DFTX Definium TherapeuticsBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 2 Jun 2025filed 2 Jun 2025 | DFTX Definium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 2 Dec 2024filed 2 Dec 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —139,380 | filing |
| 2 Dec 2024filed 2 Dec 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —90,000 | filing |
| 2 Dec 2024filed 2 Dec 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —119,700 | filing |
| 2 Dec 2024filed 2 Dec 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —90,580 | filing |
| 2 Dec 2024filed 2 Dec 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,090 | filing |
| 2 Dec 2024filed 2 Dec 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —7,900 | filing |
| 25 Oct 2024filed 29 Oct 2024 | Longboard Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —7,900 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.